Regulation of tumor angiogenesis by the local environment

Frontiers in Bioscience

Volumn 15, Issue 1, 2010, Pages 195-212

  Hall, Kelly ^a   Ran, Sophia ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiopoietins; Anti angiogenic targets; Review; Tumor environment; VEGF A

Indexed keywords

ANGIOPOIETIN 1; MEMBRANE PROTEIN; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN; VASCULOTROPIN A;

ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; VASCULARIZATION;

ANGIOPOIETIN-1; ANIMALS; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, NOTCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951227230     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3615     Document Type: Article

References (204)

1. D. Fukumura and R. K. Jain: Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101, 937-949 (2007). (Pubitemid 47040874)
2. P. Baluk, S. Morikawa, A. Haskell, M. Mancuso, and D. M. McDonald: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163, 1801-1815 (2003). (Pubitemid 37310012)
3. D. M. Noonan, Barbaro A. De Lerma, N. Vannini, L. Mortara, and A. Albini: Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27, 31-40 (2008).
4. I. Gouin-Thibault, A. Achkar, and M. M. Samama: The thrombophilic state in cancer patients. Acta Haematol 106, 33-42 (2001). (Pubitemid 32830514)
5. S. Morikawa, P. Baluk, T. Kaidoh, A. Haskell, R. K. Jain, and D. M. McDonald: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160, 985-1000 (2002). (Pubitemid 34224587)
6. G. Bergers and L. E. Benjamin: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410 (2003). (Pubitemid 37328844)
7. M. Inoue, J. H. Hager, N. Ferrara, H. P. Gerber, and D. Hanahan: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1, 193-202 (2002). (Pubitemid 41039165)
8. A. M. Byrne, D. J. Bouchier-Hayes, and J. H. Harmey: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9, 777- 794 (2005). (Pubitemid 43116546)
9. E. Barbera-Guillem, J. K. Nyhus, C. C. Wolford, C. R. Friece, and J. W. Sampsel: Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62, 7042- 7049 (2002). (Pubitemid 35424099)
10. J. H. Harmey, E. Dimitriadis, E. Kay, H. P. Redmond, and D. Bouchier-Hayes: Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 5, 271-278 (1998). (Pubitemid 28249320)
11. R. Evans, M. Fong, J. Fuller, S. Kamdar, J. Meyerhardt, and G. Strassmann: Tumor cell IL-6 gene expression is regulated by IL-1 alpha/beta and TNF alpha: proposed feedback mechanisms induced by the interaction of tumor cells and macrophages. J Leukoc Biol 52, 463-468 (1992).
12. R. M. bdel-Majid and J. S. Marshall: Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 172, 1227-1236 (2004). (Pubitemid 38113786)
13. M. McCourt, J. H. Wang, S. Sookhai, and H. P. Redmond: Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 134, 1325- 1331 (1999).
14. N. P. McCabe, S. H. Selman, and J. Jankun: Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate 66, 779-787 (2006).
15. L. Hlatky, C. Tsionou, P. Hahnfeldt, and C. N. Coleman: Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 54, 6083-6086 (1994).
16. I. Nilsson, M. Shibuya, and S. Wennstrom: Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299, 476-485 (2004). (Pubitemid 39179813)
17. B. Berse, L. F. Brown, Water L. Van de, H. F. Dvorak, and D. R. Senger: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3, 211-220 (1992). (Pubitemid 23084552)
18. D. Ribatti: The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 128, 303-309 (2005). (Pubitemid 40216151)
19. T. Asahara, T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver, and J. M. Isner: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18, 3964-3972 (1999). (Pubitemid 29335849)
20. M. Clauss: Functions of the VEGF receptor-1 (FLT- 1) in the vasculature. Trends Cardiovasc Med 8, 241- 245 (1998). (Pubitemid 28402291)
21. R. D. Meyer, M. Mohammadi, and N. Rahimi: A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem 281, 867-875 (2006).
22. M. Weigand, P. Hantel, R. Kreienberg, and J. Waltenberger: Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8, 197-204 (2005). (Pubitemid 41759144)
23. Y. Wu, A. T. Hooper, Z. Zhong, L. Witte, P. Bohlen, S. Rafii, and D. J. Hicklin: The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer (2006).
24. B. Bussolati, C. Dunk, M. Grohman, C. D. Kontos, J. Mason, and A. Ahmed: Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159, 993-1008 (2001). (Pubitemid 32847190)
25. I. Sher, S. A. Adham, J. Petrik, and B. L. Coomber: Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124, 553-561 (2008).
26. C. E. Clarkin, R. J. Emery, A. A. Pitsillides, and C. P. Wheeler-Jones: Evaluation of VEGF-mediated signaling in primary human cells reveals a paracrine action for VEGF in osteoblast-mediated crosstalk to endothelial cells. J Cell Physiol 214, 537-544 (2008). (Pubitemid 350309010)
27. Y. Herzog, C. Kalcheim, N. Kahane, R. Reshef, and G. Neufeld: Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 109, 115-119 (2001). (Pubitemid 33035924)
28. L. M. Ellis: The role of neuropilins in cancer. Mol Cancer Ther 5, 1099-1107 (2006). (Pubitemid 43881301)
29. L. Yuan, D. Moyon, L. Pardanaud, C. Breant, M. J. Karkkainen, K. Alitalo, and A. Eichmann: Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129, 4797-4806 (2002). (Pubitemid 35282411)
30. M. Klagsbrun and A. Eichmann: A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 16, 535-548 (2005). (Pubitemid 41022016)
31. M. Murga, O. Fernandez-Capetillo, and G. Tosato: Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105, 1992-1999 (2005). (Pubitemid 40731783)
32. Z. Gluzman-Poltorak, T. Cohen, M. Shibuya, and G. Neufeld: Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 276, 18688- 18694 (2001).
33. G. Neufeld, O. Kessler, and Y. Herzog: The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 515, 81-90 (2002). (Pubitemid 36324184)
34. M. Cai, H. Zhang, and R. Hui: Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem Biophys Res Commun 309, 946-951 (2003). (Pubitemid 37122621)
35. A. Latil, I. Bieche, S. Pesche, A. Valeri, G. Fournier, O. Cussenot, and R. Lidereau: VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 89, 167- 171 (2000). (Pubitemid 30185926)
36. T. Baba, M. Kariya, T. Higuchi, M. Mandai, N. Matsumura, E. Kondoh, M. Miyanishi, K. Fukuhara, K. Takakura, and S. Fujii: Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. Gynecol Oncol 105, 703-711 (2007). (Pubitemid 46734196)
37. M. J. Gray, Buren G. Van, N. A. Dallas, L. Xia, X. Wang, A. D. Yang, R. J. Somcio, Y. G. Lin, S. Lim, F. Fan, L. S. Mangala, T. Arumugam, C. D. Logsdon, G. Lopez-Berestein, A. K. Sood, and L. M. Ellis: Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100, 109- 120 (2008). (Pubitemid 351480563)
38. A. A. Parikh, W. B. Liu, F. Fan, O. Stoeltzing, N. Reinmuth, C. J. Bruns, C. D. Bucana, D. B. Evans, and L. M. Ellis: Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98, 720-729 (2003). (Pubitemid 36959267)
39. S. Frede, U. Berchner-Pfannschmidt, and J. Fandrey: Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol 435, 405-419 (2007).
40. E. B. Rankin and A. J. Giaccia: The role of hypoxiainducible factors in tumorigenesis. Cell Death Differ 15, 678-685 (2008).
41. J. A. Forsythe, B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16, 4604-4613 (1996). (Pubitemid 26272112)
42. G. L. Semenza: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 19, 59-65 (2000). (Pubitemid 32004693)
43. S. Rasheed, P. J. McDonald, J. M. Northover, and T. Guenther: Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract 204, 501-510 (2008).
44. D. J. Brat, B. Kaur, and E. G. Van Meir: Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 8, d100-d116 (2003). (Pubitemid 39069966)
45. A. Giatromanolaki, E. Sivridis, C. Simopoulos, A. Polychronidis, K. C. Gatter, A. L. Harris, and M. I. Koukourakis: Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 94, 242-247 (2006). (Pubitemid 44289989)
46. M. Kawaguchi, M. Akagi, M. J. Gray, W. Liu, F. Fan, and L. M. Ellis: Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1beta. Surgery 136, 686-692 (2004). (Pubitemid 39186584)
47. H. H. Yeh, W. W. Lai, H. H. Chen, H. S. Liu, and W. C. Su: Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25, 4300-4309 (2006). (Pubitemid 44100500)
48. S. P. Huang, M. S. Wu, C. T. Shun, H. P. Wang, M. T. Lin, M. L. Kuo, and J. T. Lin: Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11, 517-527 (2004).
49. S. Huang, J. B. Robinson, A. Deguzman, C. D. Bucana, and I. J. Fidler: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60, 5334-5339 (2000).
50. Q. Tong, L. Zheng, L. Lin, B. Li, D. Wang, C. Huang, and D. Li: VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-kappaB signaling pathway. Respir Res 7, 37 (2006).
51. S. I. Zittermann and A. C. Issekutz: Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J Leukoc Biol 80, 247-257 (2006). (Pubitemid 44835498)
52. K. Ohtani, K. Egashira, K. Hiasa, Q. Zhao, S. Kitamoto, M. Ishibashi, M. Usui, S. Inoue, Y. Yonemitsu, K. Sueishi, M. Sata, M. Shibuya, and K. Sunagawa: Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation 110, 2444-2452 (2004). (Pubitemid 39407352)
53. S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68, 4340-4346 (2008).
54. G. Chakraborty, S. Jain, and G. C. Kundu: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68, 152-161 (2008). (Pubitemid 351380116)
55. A. Sawano, T. Takahashi, S. Yamaguchi, and M. Shibuya: The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. Biochem Biophys Res Commun 238, 487-491 (1997). (Pubitemid 27464413)
56. E. Landgren, P. Schiller, Y. Cao, and L. Claesson-Welsh: Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16, 359-367 (1998). (Pubitemid 28052290)
57. J. Kroll and J. Waltenberger: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272, 32521-32527 (1997). (Pubitemid 28011938)
58. H. P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B. A. Keyt, V. Dixit, and N. Ferrara: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273, 30336-30343 (1998). (Pubitemid 28545503)
59. P. Parsons-Wingerter, U. M. Chandrasekharan, T. L. McKay, K. Radhakrishnan, P. E. DiCorleto, B. Albarran, and A. G. Farr: A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. Microvasc Res 72, 91-100 (2006). (Pubitemid 44692750)
60. J. Kroll and J. Waltenberger: VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252, 743-746 (1998). (Pubitemid 28556847)
61. H. Oh, H. Takagi, K. Suzuma, A. Otani, M. Matsumura, and Y. Honda: Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274, 15732-15739 (1999).
62. P. Carmeliet and R. K. Jain: Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
63. F. Bach, F. J. Uddin, and D. Burke: Angiopoietins in malignancy. Eur J Surg Oncol 33, 7-15 (2007). (Pubitemid 46156618)
64. C. R. Tait and P. F. Jones: Angiopoietins in tumours: the angiogenic switch. J Pathol 204, 1-10 (2004). (Pubitemid 39214476)
65. P. C. Maisonpierre, C. Suri, P. F. Jones, S. Bartunkova, S. J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T. H. Aldrich, N. Papadopoulos, T. J. Daly, S. Davis, T. N. Sato, and G. D. Yancopoulos: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997). (Pubitemid 27450643)
66. L. Eklund and B. R. Olsen: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312, 630-641 (2006). (Pubitemid 43290339)
67. H. Schnurch and W. Risau: Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119, 957-968 (1993). (Pubitemid 23337434)
68. C. Schliemann, R. Bieker, T. Padro, T. Kessler, H. Hintelmann, T. Buchner, W. E. Berdel, and R. M. Mesters: Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 91, 1203-1211 (2006). (Pubitemid 44408430)
69. M. Yano, A. Iwama, H. Nishio, J. Suda, G. Takada, and T. Suda: Expression and function of murine receptor tyrosine kinases, TIE and TEK, in hematopoietic stem cells. Blood 89, 4317-4326 (1997). (Pubitemid 27260239)
70. A. Sato, A. Iwama, N. Takakura, H. Nishio, G. D. Yancopoulos, and T. Suda: Characterization of TEK receptor tyrosine kinase and its ligands, Angiopoietins, in human hematopoietic progenitor cells. Int Immunol 10, 1217-1227 (1998). (Pubitemid 28362697)
71. N. Jones, K. Iljin, D. J. Dumont, and K. Alitalo: Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2, 257- 267 (2001). (Pubitemid 33676968)
72. E. Hofer and B. Schweighofer: Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97, 355-363 (2007). (Pubitemid 46437796)
73. W. S. Shim, I. A. Ho, and P. E. Wong: Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5, 655-665 (2007). (Pubitemid 47105484)
74. U. Fiedler and H. G. Augustin: Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27, 552-558 (2006). (Pubitemid 44780853)
75. C. Morrissey, L. D. True, M. P. Roudier, I. M. Coleman, S. Hawley, P. S. Nelson, R. Coleman, Y. C. Wang, E. Corey, P. H. Lange, C. S. Higano, and R. L. Vessella: Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007).
76. I. Takanami: Overexpression of Ang-2 mRNA in nonsmall cell lung cancer: association with angiogenesis and poor prognosis. Oncol Rep 12, 849-853 (2004).
77. J. Wang, K. Wu, D. Zhang, H. Tang, H. Xie, L. Hong, Y. Pan, M. Lan, S. Hu, X. Ning, and D. Fan: Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun 337, 386-393 (2005). (Pubitemid 41393807)
78. M. J. Currie, S. P. Gunningham, K. Turner, C. Han, P. A. Scott, B. A. Robinson, W. Chong, A. L. Harris, and S. B. Fox: Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 198, 502-510 (2002). (Pubitemid 35447003)
79. J. H. Park, K. J. Park, Y. S. Kim, S. S. Sheen, K. S. Lee, H. N. Lee, Y. J. Oh, and S. C. Hwang: Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132, 200-206 (2007).
80. P. Szlosarek, K. A. Charles, and F. R. Balkwill: Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42, 745-750 (2006).
81. G. J. Caine, A. D. Blann, P. S. Stonelake, P. Ryan, and G. Y. Lip: Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 33, 883-890 (2003). (Pubitemid 37215044)
82. C. Sfiligoi, A. de Luca, I. Cascone, V. Sorbello, L. Fuso, R. Ponzone, N. Biglia, E. Audero, R. Arisio, F. Bussolino, P. Sismondi, and M. De Bortoli: Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103, 466-474 (2003). (Pubitemid 36020220)
83. Y. C. Chung, Y. C. Hou, C. N. Chang, and T. H. Hseu: Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 94, 631-638 (2006).
84. T. Nakayama, G. Hatachi, C. Y. Wen, A. Yoshizaki, K. Yamazumi, D. Niino, and I. Sekine: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol 11, 964- 969 (2005). (Pubitemid 40347746)
85. S. A. Ahmad, W. Liu, Y. D. Jung, F. Fan, N. Reinmuth, C. D. Bucana, and L. M. Ellis: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92, 1138-1143 (2001). (Pubitemid 32861662)
86. C. E. Lewis, Palma M. De, and L. Naldini: Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67, 8429-8432 (2007). (Pubitemid 47437413)
87. S. J. Mandriota and M. S. Pepper: Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83, 852-859 (1998). (Pubitemid 28489082)
88. S. J. Mandriota, C. Pyke, Sanza C. Di, P. Quinodoz, B. Pittet, and M. S. Pepper: Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 156, 2077-2089 (2000). (Pubitemid 30641775)
89. C. Willam, P. Koehne, J. S. Jurgensen, M. Grafe, K. D. Wagner, S. Bachmann, U. Frei, and K. U. Eckardt: Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 87, 370-377 (2000).
90. C. Conte, E. Riant, C. Toutain, F. Pujol, J. F. Arnal, F. Lenfant, and A. C. Prats: FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha. PLoS ONE 3, e3078 (2008).
91. K. J. Lavine, A. C. White, C. Park, C. S. Smith, K. Choi, F. Long, C. C. Hui, and D. M. Ornitz: Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. Genes Dev 20, 1651-1666 (2006). (Pubitemid 43901103)
92. A. Hegen, S. Koidl, K. Weindel, D. Marme, H. G. Augustin, and U. Fiedler: Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 24, 1803-1809 (2004). (Pubitemid 39350295)
93. J. Holash, P. C. Maisonpierre, D. Compton, P. Boland, C. R. Alexander, D. Zagzag, G. D. Yancopoulos, and S. J. Wiegand: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999). (Pubitemid 29309448)
94. T. Etoh, H. Inoue, S. Tanaka, G. F. Barnard, S. Kitano, and M. Mori: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61, 2145- 2153 (2001). (Pubitemid 32692040)
95. B. Hu, P. Guo, Q. Fang, H. Q. Tao, D. Wang, M. Nagane, H. J. Huang, Y. Gunji, R. Nishikawa, K. Alitalo, W. K. Cavenee, and S. Y. Cheng: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 100, 8904- 8909 (2003). (Pubitemid 36899196)
96. A. Noel, M. Jost, and E. Maquoi: Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 19, 52-60 (2008). (Pubitemid 350235981)
97. S. Suchting, C. Freitas, Noble F. le, R. Benedito, C. Breant, A. Duarte, and A. Eichmann: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 104, 3225-3230 (2007). (Pubitemid 46364141)
98. N. S. Patel, J. L. Li, D. Generali, R. Poulsom, D. W. Cranston, and A. L. Harris: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65, 8690-8697 (2005). (Pubitemid 41377356)
99. M. Hellstrom, L. K. Phng, J. J. Hofmann, E. Wallgard, L. Coultas, P. Lindblom, J. Alva, A. K. Nilsson, L. Karlsson, N. Gaiano, K. Yoon, J. Rossant, M. L. Iruela-Arispe, M. Kalen, H. Gerhardt, and C. Betsholtz: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007). (Pubitemid 46279716)
100. W. R. Gordon, D. Vardar-Ulu, G. Histen, C. Sanchez-Irizarry, J. C. Aster, and S. C. Blacklow: Structural basis for autoinhibition of Notch. Nat Struct Mol Biol 14, 295- 300 (2007). (Pubitemid 46608349)
101. R. C. Sainson, J. Aoto, M. N. Nakatsu, M. Holderfield, E. Conn, E. Koller, and C. C. Hughes: Cellautonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J 19, 1027-1029 (2005). (Pubitemid 40827740)
102. L. S. Harrington, R. C. Sainson, C. K. Williams, J. M. Taylor, W. Shi, J. L. Li, and A. L. Harris: Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 75, 144- 154 (2008). (Pubitemid 351249857)
103. C. K. Williams, J. L. Li, M. Murga, A. L. Harris, and G. Tosato: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939 (2006). (Pubitemid 43156289)
104. N. S. Patel, M. S. Dobbie, M. Rochester, G. Steers, R. Poulsom, Monnier K. Le, D. W. Cranston, J. L. Li, and A. L. Harris: Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 12, 4836-4844 (2006). (Pubitemid 44338568)
105. M. Segarra, C. K. Williams, Mde L. Sierra, M. Bernardo, P. J. McCormick, D. Maric, C. Regino, P. Choyke, and G. Tosato: Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112, 1904-1911 (2008).
106. I. Noguera-Troise, C. Daly, N. J. Papadopoulos, S. Coetzee, P. Boland, N. W. Gale, H. C. Lin, G. D. Yancopoulos, and G. Thurston: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006). (Pubitemid 46018516)
107. K. Holmqvist, M. J. Cross, C. Rolny, R. Hagerkvist, N. Rahimi, T. Matsumoto, L. Claesson-Welsh, and M. Welsh: The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279, 22267-22275 (2004). (Pubitemid 38679423)
108. K. Hattori, S. Dias, B. Heissig, N. R. Hackett, D. Lyden, M. Tateno, D. J. Hicklin, Z. Zhu, L. Witte, R. G. Crystal, M. A. Moore, and S. Rafii: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193, 1005-1014 (2001). (Pubitemid 32436194)
109. B. Witzenbichler, P. C. Maisonpierre, P. Jones, G. D. Yancopoulos, and J. M. Isner: Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273, 18514- 18521 (1998). (Pubitemid 28334780)
110. Y. Mochizuki, T. Nakamura, H. Kanetake, and S. Kanda: Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 115, 175-183 (2002). (Pubitemid 34105540)
111. I. Kim, J. H. Kim, S. O. Moon, H. J. Kwak, N. G. Kim, and G. Y. Koh: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19, 4549-4552 (2000).
112. K. L. Kim, I. S. Shin, J. M. Kim, J. H. Choi, J. Byun, E. S. Jeon, W. Suh, and D. K. Kim: Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc Res 72, 394-402 (2006). (Pubitemid 44665844)
113. R. Montesano, J. V. Soriano, K. M. Malinda, M. L. Ponce, A. Bafico, H. K. Kleinman, D. P. Bottaro, and S. A. Aaronson: Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 9, 355-365 (1998). (Pubitemid 28345875)
114. R. Abounader and J. Laterra: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7, 436-451 (2005). (Pubitemid 41555616)
115. M. J. Cross and L. Claesson-Welsh: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22, 201-207 (2001). (Pubitemid 32244307)
116. C. Charalambous, L. B. Pen, Y. S. Su, J. Milan, T. C. Chen, and F. M. Hofman: Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res 65, 10347-10354 (2005). (Pubitemid 41743727)
117. J. S. Yao, W. Zhai, W. L. Young, and G. Y. Yang: Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 342, 1396-1404 (2006).
118. G. Rennebeck, M. Martelli, and N. Kyprianou: Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res 65, 11230-11235 (2005). (Pubitemid 41821673)
119. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, D. J. Hicklin, P. Bohlen, and R. S. Kerbel: Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, R15-R24 (2000). (Pubitemid 30217701)
120. C. J. Bruns, W. Liu, D. W. Davis, R. M. Shaheen, D. J. McConkey, M. R. Wilson, C. D. Bucana, D. J. Hicklin, and L. M. Ellis: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89, 488-499 (2000). (Pubitemid 30640095)
121. L. W. Wu, L. D. Mayo, J. D. Dunbar, K. M. Kessler, M. R. Baerwald, E. A. Jaffe, D. Wang, R. S. Warren, and D. B. Donner: Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 275, 5096-5103 (2000). (Pubitemid 30108910)
122. A. Papapetropoulos, D. Fulton, K. Mahboubi, R. G. Kalb, D. S. O'Connor, F. Li, D. C. Altieri, and W. C. Sessa: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275, 9102-9105 (2000). (Pubitemid 30185122)
123. A. J. Hayes, W. Q. Huang, J. Mallah, D. Yang, M. E. Lippman, and L. Y. Li: Angiopoietin-1 and its receptor Tie- 2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res 58, 224-237 (1999). (Pubitemid 29531872)
124. D. Yin, C. Li, R. L. Kao, T. Ha, G. Krishnaswamy, M. Fitzgerald, and C. A. Stuart: Angiopoietin-1 inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating fas expression and via the PI3K/Akt pathway. Endothelium 11, 247-252 (2004). (Pubitemid 40123392)
125. D. Langford, R. Hurford, M. Hashimoto, M. Digicaylioglu, and E. Masliah: Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIVgp120. BMC Neurosci 6, 8 (2005).
126. J. Yu, C. Ustach, and H. R. Kim: Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36, 49-59 (2003). (Pubitemid 36836256)
127. V. S. Rajkumar, X. Shiwen, M. Bostrom, P. Leoni, J. Muddle, M. Ivarsson, B. Gerdin, C. P. Denton, G. Bou-Gharios, C. M. Black, and D. J. Abraham: Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 169, 2254-2265 (2006). (Pubitemid 351181983)
128. A. Abramsson, P. Lindblom, and C. Betsholtz: Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112, 1142-1151 (2003). (Pubitemid 38056291)
129. J. Zhang, R. Cao, Y. Zhang, T. Jia, Y. Cao, and E. Wahlberg: Differential roles of PDGFR-{alpha} and PDGFR-{beta} in angiogenesis and vessel stability. FASEB J (2008).
130. M. R. Kano, Y. Morishita, C. Iwata, S. Iwasaka, T. Watabe, Y. Ouchi, K. Miyazono, and K. Miyazawa: VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118, 3759-3768 (2005). (Pubitemid 41309422)
131. D. Yoshida, K. Kim, M. Noha, and A. Teramoto: Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76, 13-21 (2006). (Pubitemid 43115754)
132. R. Bos, P. J. van Diest, J. S. de Jong, Groep P. van der, der van, V, and Wall E. van-der: Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46, 31-36 (2005). (Pubitemid 40193695)
133. C. S. Milner, T. M. Hansen, H. Singh, and N. P. Brindle: Roles of the receptor tyrosine kinases Tie1 and Tie2 in mediating the effects of angiopoietin-1 on endothelial permeability and apoptosis. Microvasc Res (2008).
134. J. Cai, O. Kehoe, G. M. Smith, P. Hykin, and M. E. Boulton: The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49, 2163-2171 (2008).
135. H. Kobayashi, L. M. DeBusk, Y. O. Babichev, D. J. Dumont, and P. C. Lin: Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 108, 1260-1266 (2006). (Pubitemid 44232023)
136. Y. Nakamura, F. Tanaka, Y. Yoshikawa, K. Mimori, H. Inoue, K. Yanaga, and M. Mori: PDGF-BB is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 15, 2129-2136 (2008).
137. M. L. Fjallskog, O. Hessman, B. Eriksson, and E. T. Janson: Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 46, 741-746 (2007). (Pubitemid 47123755)
138. E. T. Shinohara, A. Gonzalez, P. P. Massion, S. J. Olson, J. M. Albert, Y. Shyr, D. P. Carbone, D. H. Johnson, D. E. Hallahan, and B. Lu: PDGFR-beta expression in small cell lung cancer patients. Int J Radiat Oncol Biol Phys 67, 431-437 (2007). (Pubitemid 46108305)
139. Bender J. Glade, E. M. Cooney, J. J. Kandel, and D. J. Yamashiro: Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7, 289- 300 (2004). (Pubitemid 39469101)
140. N. Weidner, P. R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143, 401-409 (1993). (Pubitemid 24058195)
141. D. M. McDonald and P. L. Choyke: Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713- 725 (2003). (Pubitemid 36749220)
142. P. Vajkoczy and M. D. Menger: Vascular microenvironment in gliomas. J Neurooncol 50, 99-108 (2000). (Pubitemid 32166294)
143. D. Fukumura and R. K. Jain: Imaging angiogenesis and the microenvironment. APMIS 116, 695-715 (2008).
144. H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain, and D. M. McDonald: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156, 1363-1380 (2000). (Pubitemid 30660013)
145. M. K. Gupta and R. Y. Qin: Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9, 1144-1155 (2003). (Pubitemid 36805642)
146. B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh: The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61, 2256-2260 (2001). (Pubitemid 32692056)
147. P. Barrett-Lee, M. Travers, Y. Luqmani, and R. C. Coombes: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61, 612- 617 (1990). (Pubitemid 20126345)
148. Y. Xu and Q. Yu: Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 276, 34990-34998 (2001).
149. N. Ferrara: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl 1, 2-10 (2004). (Pubitemid 38747842)
150. H. P. Gerber and N. Ferrara: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65, 671-680 (2005). (Pubitemid 40216420)
151. N. Ferrara, K. J. Hillan, and W. Novotny: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333, 328-335 (2005). (Pubitemid 40848295)
152. M. A. Cobleigh, V. K. Langmuir, G. W. Sledge, K. D. Miller, L. Haney, W. F. Novotny, J. D. Reimann, and A. Vassel: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30, 117-124 (2003). (Pubitemid 37433402)
153. K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, V. Langmuir, and H. S. Rugo: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23, 792-799 (2005). (Pubitemid 46224178)
154. R. K. Jain: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58- 62 (2005). (Pubitemid 40093472)
155. R. K. Jain: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989 (2001). (Pubitemid 32937367)
156. R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, and R. K. Jain: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731-3736 (2004). (Pubitemid 38697278)
157. C. G. Willett, Y. Boucher, Tomaso E. di, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva, S. V. Kozin, M. Mino, K. S. Cohen, D. T. Scadden, A. C. Hartford, A. J. Fischman, J. W. Clark, D. P. Ryan, A. X. Zhu, L. S. Blaszkowsky, H. X. Chen, P. C. Shellito, G. Y. Lauwers, and R. K. Jain: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147 (2004). (Pubitemid 38524883)
158. J. Ridgway, G. Zhang, Y. Wu, S. Stawicki, W. C. Liang, Y. Chanthery, J. Kowalski, R. J. Watts, C. Callahan, I. Kasman, M. Singh, M. Chien, C. Tan, J. A. Hongo, Sauvage F. de, G. Plowman, and M. Yan: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006). (Pubitemid 46018529)
159. Y. Hasumi, A. Klosowska-Wardega, M. Furuhashi, A. Ostman, C. H. Heldin, and C. Hellberg: Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121, 2606-2614 (2007). (Pubitemid 350136402)
160. D. J. George: Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res 13, 753s-757s (2007).
161. A. Fontana, S. Filleur, J. Guglielmi, L. Frappart, G. Bruno-Bossio, S. Boissier, F. Cabon, and P. Clezardin: Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer 116, 686- 691 (2005). (Pubitemid 41099699)
162. E. Mylona, P. Alexandrou, I. Giannopoulou, G. Liapis, M. Sofia, A. Keramopoulos, and L. Nakopoulou: The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol 104, 557-563 (2007).
163. M. Ohta, Y. Kitadai, S. Tanaka, M. Yoshihara, W. Yasui, N. Mukaida, K. Haruma, and K. Chayama: Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 22, 773-778 (2003).
164. J. B. Jia, P. Y. Zhuang, H. C. Sun, J. B. Zhang, W. Zhang, X. D. Zhu, Y. Q. Xiong, H. X. Xu, and Z. Y. Tang: Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol (2008).
165. S. Brychtova, M. Bezdekova, T. Brychta, and M. Tichy: The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 55, 273-279 (2008).
166. T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. N. Nilsen, L. T. Busund, and R. M. Bremnes: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13, 6649-6657 (2007). (Pubitemid 350206800)
167. T. Mainou-Fowler, B. Angus, S. Miller, S. J. Proctor, P. R. Taylor, and K. M. Wood: Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 47, 223-230 (2006). (Pubitemid 43084560)
168. S. Inan, S. Vatansever, C. Celik-Ozenci, M. Sanci, N. Dicle, and R. Demir: Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21, 1055-1064 (2006). (Pubitemid 44614486)
169. S. Arita, F. Kikkawa, H. Kajiyama, K. Shibata, M. Kawai, K. Mizuno, T. Nagasaka, K. Ino, and S. Nomura: Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Int J Gynecol Cancer 15, 329-336 (2005). (Pubitemid 40396974)
170. R. G. Bagley, C. Rouleau, S. D. Morgenbesser, W. Weber, B. P. Cook, S. Shankara, S. L. Madden, and B. A. Teicher: Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy. Microvasc Res 71, 163-174 (2006). (Pubitemid 43794852)
171. R. V. Lalla, D. S. Boisoneau, J. D. Spiro, and D. L. Kreutzer: Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 129, 882- 888 (2003). (Pubitemid 36966435)
172. G. Xia, S. R. Kumar, D. Hawes, J. Cai, L. Hassanieh, S. Groshen, S. Zhu, R. Masood, D. I. Quinn, D. Broek, J. P. Stein, and P. S. Gill: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175, 1245-1252 (2006).
173. A. Giatromanolaki, M. I. Koukourakis, E. Sivridis, G. Chlouverakis, E. Vourvouhaki, H. Turley, A. L. Harris, and K. C. Gatter: Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 37, 878-886 (2007). (Pubitemid 350029203)
174. R. Yamaguchi, H. Yano, Y. Nakashima, S. Ogasawara, K. Higaki, J. Akiba, D. J. Hicklin, and M. Kojiro: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7, 725-729 (2000).
175. A. A. Parikh, F. Fan, W. B. Liu, S. A. Ahmad, O. Stoeltzing, N. Reinmuth, D. Bielenberg, C. D. Bucana, M. Klagsbrun, and L. M. Ellis: Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 164, 2139-2151 (2004). (Pubitemid 38669361)
176. S. Lantuejoul, B. Constantin, H. Drabkin, C. Brambilla, J. Roche, and E. Brambilla: Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 200, 336-347 (2003). (Pubitemid 36827308)
177. G. H. Hall, L. W. Turnbull, K. Bedford, I. Richmond, L. Helboe, and S. L. Atkin: Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours. Int J Oncol 27, 1283-1288 (2005).
178. M. Li, H. Yang, H. Chai, W. E. Fisher, X. Wang, F. C. Brunicardi, Q. Yao, and C. Chen: Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 101, 2341-2350 (2004). (Pubitemid 39458692)
179. M. Fakhari, D. Pullirsch, D. Abraham, K. Paya, R. Hofbauer, P. Holzfeind, M. Hofmann, and S. Aharinejad: Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 94, 258-263 (2002). (Pubitemid 34049067)
180. C. Onofri, M. Theodoropoulou, M. Losa, E. Uhl, M. Lange, E. Arzt, G. K. Stalla, and U. Renner: Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a nonendothelial function of VEGF in pituitary tumours. J Endocrinol 191, 249-261 (2006). (Pubitemid 44756527)
181. T. Cohen, Y. Herzog, A. Brodzky, J. K. Greenson, S. Eldar, Z. Gluzman-Poltorak, G. Neufeld, and M. B. Resnick: Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J Pathol 198, 77-82 (2002). (Pubitemid 34966210)
182. J. R. Jackson, J. A. Minton, M. L. Ho, N. Wei, and J. D. Winkler: Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol 24, 1253-1259 (1997). (Pubitemid 27353364)
183. T. Tanaka, H. Kanai, K. Sekiguchi, Y. Aihara, T. Yokoyama, M. Arai, T. Kanda, R. Nagai, and M. Kurabayashi: Induction of VEGF gene transcription by IL- 1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J Mol Cell Cardiol 32, 1955-1967 (2000).
184. M. Li, Y. Zhang, L. W. Feurino, H. Wang, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao: Interleukin- 8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci 99, 733-737 (2008). (Pubitemid 351448077)
185. A. G. Lowrie, D. M. Salter, and J. A. Ross: Latent effects of fibronectin, alpha5beta1 integrin, alphaVbeta5 integrin and the cytoskeleton regulate pancreatic carcinoma cell IL-8 secretion. Br J Cancer 91, 1327-1334 (2004). (Pubitemid 39424794)
186. S. Wei, J. H. Liu, D. K. Blanchard, and J. Y. Djeu: Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol 152, 3630-3636 (1994). (Pubitemid 24098061)
187. M. L. Cho, Y. O. Jung, Y. M. Moon, S. Y. Min, C. H. Yoon, S. H. Lee, S. H. Park, C. S. Cho, D. M. Jue, and H. Y. Kim: Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 103, 159-166 (2006). (Pubitemid 43162931)
188. S. Lebel-Binay, N. Thiounn, G. De-Pinieux, A. Vieillefond, B. Debre, J. Y. Bonnefoy, W. H. Fridman, and F. Pages: IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 106, 827- 835 (12003).
189. M. N. Manoussakis, S. Boiu, P. Korkolopoulou, E. K. Kapsogeorgou, N. Kavantzas, P. Ziakas, E. Patsouris, and H. M. Moutsopoulos: Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 56, 3977-3988 (2007). (Pubitemid 350262325)
190. M. M. Queen, R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, and C. L. Jorcyk: Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65, 8896-8904 (2005). (Pubitemid 41377379)
191. M. Burger, A. Glodek, T. Hartmann, A. Schmitt-Graff, L. E. Silberstein, N. Fujii, T. J. Kipps, and J. A. Burger: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22, 8093-8101 (2003). (Pubitemid 37487300)
192. S. Kitamura, Y. Maeshima, T. Sugaya, H. Sugiyama, Y. Yamasaki, and H. Makino: Transforming growth factorbeta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 95, e79-e86 (2003).
193. M. Pilichowska, N. Kimura, H. Fujiwara, and H. Nagura: Immunohistochemical study of TGF-alpha, TGFbeta1, EGFR, and IGF-1 expression in human breast carcinoma. Mod Pathol 10, 969-975 (1997). (Pubitemid 27471116)
194. M. Niiya, K. Niiya, T. Kiguchi, M. Shibakura, N. Asaumi, K. Shinagawa, F. Ishimaru, K. Kiura, K. Ikeda, H. Ueoka, and M. Tanimoto: Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 52, 391-398 (2003). (Pubitemid 37363612)
195. J. Nakagawa, M. Saio, N. Tamakawa, T. Suwa, A. B. Frey, K. Nonaka, N. Umemura, H. Imai, G. F. Ouyang, N. Ohe, H. Yano, S. Yoshimura, T. Iwama, and T. Takami: TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma. Int J Oncol 30, 803-811 (2007).
196. N. Oka, Y. Yamamoto, M. Takahashi, M. Nishitani, H. O. Kanayama, and S. Kagawa: Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 95, 660-663 (2005). (Pubitemid 40311493)
197. S. Tsutsui, H. Inoue, K. Yasuda, K. Suzuki, H. Takeuchi, T. Nishizaki, H. Higashi, S. Era, and M. Mori: Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 98, 261-266 (2006). (Pubitemid 44195595)
198. K. Koga, T. Todaka, M. Morioka, J. Hamada, Y. Kai, S. Yano, A. Okamura, N. Takakura, T. Suda, and Y. Ushio: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61, 6248-6254 (2001). (Pubitemid 32762564)
199. W. S. Moon, K. H. Rhyu, M. J. Kang, D. G. Lee, H. C. Yu, J. H. Yeum, G. Y. Koh, and A. S. Tarnawski: Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16, 552-557 (2003). (Pubitemid 36718436)
200. H. Wada, H. Nagano, H. Yamamoto, Y. Yang, M. Kondo, H. Ota, M. Nakamura, S. Yoshioka, H. Kato, B. Damdinsuren, D. Tang, S. Marubashi, A. Miyamoto, Y. Takeda, K. Umeshita, S. Nakamori, M. Sakon, K. Dono, K. Wakasa, and M. Monden: Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 26, 414-423 (2006).
201. Z. L. Zhang, Z. S. Liu, and Q. Sun: Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 12, 4241-4245 (2006). (Pubitemid 44376912)
202. S. Loges, H. Clausen, U. Reichelt, M. Bubenheim, A. Erbersdobler, P. Schurr, E. Yekebas, G. Schuch, J. Izbicki, K. Pantel, C. Bokemeyer, and W. Fiedler: Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13, 76-80 (2007). (Pubitemid 46121855)
203. K. Hata, K. Nakayama, R. Fujiwaki, H. Katabuchi, H. Okamura, and K. Miyazaki: Expression of the angopoietin- 1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 93, 215-222 (2004). (Pubitemid 38429573)
204. N. Reinmuth, E. Piegelbrock, M. Raedel, N. Fehrmann, H. Hintelmann, R. Wagner, W. E. Berdel, M. Thomas, L. Freitag, and R. M. Mesters: Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer 55, 53-60 (2007). (Pubitemid 46043582)